Viridian Therapeutics, Inc. (VRDN) AI Stock Analysis

Viridian Therapeutics, Inc. is a biotechnology company focused on developing transformative treatments for patients with severe diseases. The company is advancing an innovative pipeline targeting the insulin-like growth factor 1 receptor (IGF-1R), spearheaded by VRDN-001, VRDN-002, and VRDN-003. VRDN-001 is a humanized monoclonal antibody undergoing Phase 1/2 clinical trials for thyroid eye disease (TED). In addition, VRDN-002 is advancing through Phase 1 clinical trials, while VRDN-003 is being developed as a therapeutic antibody specifically for TED treatment. Founded in 2006 and headquartered in Waltham, Massachusetts, the firm previously operated as Miragen Therapeutics, Inc. before rebranding in January 2021.

Revenue historically fluctuated, dropping from $3.0M in FY2021 to $1.8M in FY2022, $314,000 in FY2023, and $302,000 in FY2024. In FY2025, revenue rose 23359.9% to $70.8M, contributing to a 5-year revenue CAGR of 132.2% from FY2020 to FY2025. Gross margin stood at 100.0% across all five years. However, net losses widened from -$79.4M in FY2021 to -$342.6M in FY2025, alongside research and development expenses expanding to $338.9M. For the latest quarter ended June 30, 2026, quarterly revenue growth was 278.7% year-over-year, while trailing twelve months revenue reached $71.1M with an operating margin of -44460.6% and eps of -$3.39.

As of June 30, 2026, Viridian Therapeutics held $981.5M in cash and short-term investments against total debt of $242.9M, yielding net cash of $738.6M. Total assets stood at $1.10B, with shareholders equity of $662.1M. The company shows solid liquidity metrics, including a current ratio of 16.95 and a debt-to-equity ratio of 0.37. Free cash flow was -$276.9M in FY2025, reflecting operating cash flow of -$276.4M and capital expenditures of $495,000. In FY2025, share issuance was $1.1M, while share count change over 5 years reached 864.7%.

Viridian Therapeutics carries a market cap of $2.16B and an enterprise value of $1.79B. The stock trades at a price-to-sales ratio of 30.3x and an ev_to_revenue of 25.1x, well above the 4.1x price-to-sales median of its US-listed Healthcare peers. Its price-to-book multiple is 4.3x, while forward P/E stands at 1.0x versus 17.3x for its peer group. Over the past year, VRDN fell 17.3%, lagging the 16.8% gain for the S&P 500 (SPY). Over 5 years, the stock gained 11.5%, while the S&P 500 returned 83.0%.

Viridian Therapeutics holds 14 Strong Buy ratings and 3 Buy ratings, with 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $36.75, representing an upside of 93.1% from the last close of $19.03. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$3.94 on revenue of $24.4M. For next fiscal year, 12 analysts project revenue of $233.6M and EPS of -$2.75. The company beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of Viridian Therapeutics, Inc. (VRDN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VRDN income statement, VRDN balance sheet, VRDN key metrics, VRDN analyst forecast, VRDN chart. See the VRDN stock overview for the latest quote and news.